期刊文献+

胃肠道恶性间质瘤诊治分析 被引量:2

Diagnosis and treatment for gastrointestinal stromal sarcomas
原文传递
导出
摘要 目的探讨胃肠道恶性间质瘤(GISS)的临床特点、病理学和免疫组化特点及诊断、治疗方法。方法对36例GISS患者的临床资料和诊断、治疗进行回顾性分析。结果GIST主要发生在胃和小肠,结肠和直肠较少;免疫组织化学检查显示CD117阳性33例(91.7%),CD34阳性31例(86.1%);随访时间6-144个月,5年生存率31.8%。结论GISS是一种少见的恶性肿瘤,其确诊有赖于病理组织学和免疫组化检查,CD34和CD117阳性在诊断上有其特殊意义;手术治疗仍是主要治疗手段。 Objective To explore the clinical behavior,pathological and immunohistochemical characteristics and diagnosis, treatment methods of gastrointestinal stromal sarcomas (GISS). Methods Retrospective analysis was perfomed over 36 GISS patients based on clinical data and pathological data. Results GISS occurred more in the stomach and small intestine, than colon and rectum, lmmunohistochemieal staining showed CD117, CD34 expression, the positive rates were 91.7% and 86. 1%. Conclusion GISS is a rare malignant tumor, GISS diagnosis depends on the histologie and immunohistochemieal test. CD34 and CD117 in the positive diagnosis has its special significance, surgery is the main treatment.
出处 《中国基层医药》 CAS 2010年第6期729-730,共2页 Chinese Journal of Primary Medicine and Pharmacy
关键词 胃肠道恶性间质瘤 诊断 治疗 GISS Diagnosis Treatment
  • 相关文献

参考文献9

二级参考文献59

共引文献297

同被引文献23

  • 1侯英勇,孙孟红,魏永昆,谭云山,陆孝禹,王坚,朱雄增,郑爱华.腹内胃肠道外间质瘤临床病理、免疫组织化学及分子遗传学研究[J].中华病理学杂志,2003,32(5):422-426. 被引量:36
  • 2Levy AD,Remotti HE,Thompson WM,et al.Gastrointestinal stromal tumors:radiologic features with pathologic correlation[J].Radiographies,2003,23(2):283-304,456.
  • 3Miettinen M,lasots J.Gastrointestinal stromal tumors:review on morphology,molecular pathology,prognosis,and differential diagnosis[J].Arch pathol Lab Med,2006,130(10):1466-78.
  • 4DeMatteo RP,Lewis JJ,Leung D,et al.Two hundred gastrointestinal stromal tumors:recurrence patterns and prognostic factors for survival[J].AnnSurg,2000,231(1):51-8.
  • 5Novitsky YW,Kercher KW,Sing RF,et al.Long-term outcomes of laparoscopic resection of gastric gastrointestinal stromal tumors.Ann Surg,2006,243(6):738-45.
  • 6中国胃肠道间质瘤病理共识意见[J].中华病理学杂志,2007,36(10):704-707. 被引量:110
  • 7Joensuu H. Risk stratification of patients diagnosed with gastroiniestinal stromal tumor[J].Human Pathology,2008,(10):1411-1419.doi:10.1016/j.humpath.2008.06.025.
  • 8Joensuu H,Roberts PJ,Sarlomo-Rikala M. Effect of the tyrosine kinase inhibitor ST1571 in a patient with a metastaticingastohtestinal stromal tumor[J].New England Journal of Medicine,2002.472-480.
  • 9Dematteo RP,Owzar K,Antonescu CR. Efficacy of adjuvant imatinib mesylate following complete resection of localized,primary gastrointestinal stromal tumor(GIST) at high risk of recurrence:the US Intergroup phase Ⅱ trial ACOSOG Z9000[M].American Society of Clinical Oncology,2008.
  • 10Gold JS,Van Der,Zwan SM. Outcome of metastatic GIST in the era before tyrosine kinase inhibitors[J].Annals of Surgical Oncology,2007.134-142.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部